1. Home
  2. ETON vs CGEM Comparison

ETON vs CGEM Comparison

Compare ETON & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eton Pharmaceuticals Inc.

ETON

Eton Pharmaceuticals Inc.

N/A

Current Price

$56.20

Market Cap

1.3B

Sector

Health Care

ML Signal

N/A

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$21.29

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ETON
CGEM
Founded
2017
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.4B
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
ETON
CGEM
Price
$56.20
$21.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
8
Target Price
$39.33
$30.13
AVG Volume (30 Days)
428.6K
719.6K
Earning Date
05-14-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$79,950,000.00
N/A
Revenue This Year
$40.90
N/A
Revenue Next Year
$47.23
$5.20
P/E Ratio
$136.12
N/A
Revenue Growth
104.94
N/A
52 Week Low
$14.27
$5.68
52 Week High
$66.37
$23.19

Technical Indicators

Market Signals
Indicator
ETON
CGEM
Relative Strength Index (RSI) 49.17 46.94
Support Level $15.75 $11.87
Resistance Level $66.37 $23.19
Average True Range (ATR) 2.54 0.98
MACD -1.32 -0.35
Stochastic Oscillator 18.40 42.27

Price Performance

Historical Comparison
ETON
CGEM

About ETON Eton Pharmaceuticals Inc.

Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has eight commercial rare disease products, INCRELEX, ALKINDI SPRINKLE, KHINDIVITM, GALZIN, PKU GOLIKE, Carglumic Acid, Betaine Anhydrous and Nitisinone. It also has five additional product candidates in late-stage development: ET-600, Amglidia, ET-700, ET-800 and ZENEO hydrocortisone autoinjector.

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

Share on Social Networks: